Close
Almac
Achema middle east

Sharp Clinical broadens global client support with Business Development appointments

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
- Advertisement -

Sharp Clinical Services, a part of UDG Healthcare and a leading provider of global clinical supply services, has added three key members to its business development team.

Katie Bracaliello, Johannes Stein and Olivier Cena have joined Sharp Clinical Services as account executive, business development director and business development manager respectively.

The appointments are part of Sharp’s strategy to broaden its global footprint and strengthen the support it can offer to current and prospective clients following a series of investments into new and enhanced capabilities.

Commenting on the appointments, Sascha Sonnenberg, newly appointed global head of business development for Sharp Clinical Services, said:

“Sharp Clinical Services has a unique suite of clinical to commercial services to offer its clients and an excellent reputation for flexibility and quality combined with new global facilities and expanded capabilities.

“Adding experienced individuals like Katie, Johannes and Olivier to the team will ensure that Sharp further expands its position as a leading partner of choice in the clinical supply market.

“I look forward to working with them and the rest of the Sharp Clinical Services team as we support pharmaceutical and biopharma clients around the world in bringing new drugs to market.”

In his new position, Johannes Stein is responsible for business development in Germany, Austria, Switzerland and the Netherlands. Johannes joins Sharp from Recipharm where he held the position of a sales director for the DACH region. He has almost 25 years’ experience in the healthcare market and holds a PhD in cancer research.

Olivier Cena, will take the lead on further developing Sharp’s client base in France, Belgium, Switzerland, Spain and Israel. He has more than 10 years’ experience in selling services to pharmaceutical companies and joins from UPS where he was responsible for raising the company’s profile as the healthcare segment marketing manager.

Katie Bracaliello’s role includes supporting and managing existing and new clients in the US west-coast territory. Katie joins Sharp from Therapak where she managed business development for global kitting solutions supply to the central lab, pharmaceutical, biotech and clinical research organization markets.

The appointments follow a string of investments made by Sharp and UDG Healthcare into clinical services capabilities including:

• £9.5 million on a Clinical Services Centre of Excellence in Wales
• $650k on enhancing its Interactive Response Technology (IRT) solution, and;
• $23 million on relocating some US services to a new state-of-the-art facility in Bethlehem, PA.

The Sharp Clinical team will be attending the upcoming Clinical Trial Supply Europe event in Madrid, Spain on 11-12 March 2020.

ABOUT SHARP

Sharp, part of UDG healthcare, is a global leader in contract packaging and clinical services. Operating from eight state-of-the-art facilities across the US and Europe, Sharp has built an international reputation for delivering cost-effective blister packaging, bottling, secondary assembly and labelling of injectable presentations, compliance packaging, formulation and manufacturing services, label design and printing. Sharp is also a world leader in ’Track and Trace’ and serialization services, with over 11 years’ experience in implementing serialized solutions for its pharma clients.

Sharp Clinical

Sharp Clinical offers a full complement of clinical trial services, including analytical, formulation development, clinical manufacturing and packaging, storage and distribution. Sharp also offers an interactive response technology (IRT) platform which can accommodate simple to complex randomization schemes as well as clinical supply chain management.

During 2018, Sharp Clinical invested $36 million in new dedicated facilities in both the US and the UK and can offer QP services for European distribution. We service every phase of the drug lifecycle from Phase 1 through to commercialization and through our global network of over 30 depots we can distribute to every region of the world. Our highly experienced team will help you optimize every aspect of your clinical trial. For more information on Sharp and its solutions, visit www.sharpservices.com

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »